Those results were in line with those of previous studies, with reports that increased SerpinB3/4–IgM levels were associated with shorter survival not only in patients with HCC [38,39] but also in patients with cirrhosis [37], a known subgroup of patients at higher risk of liver tumor development. This evidence concerns the gene SERPINB3 and hepatocellular carcinoma.